Combination DMARD therapy including corticosteroids in early rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 17, Issue 6 SUPPL. 18, 1999, Pages

  Mottonen T T ^a   Hannonen, P J ^b   Boers, M ^c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Combination; Corticosteroi ds; DMARD; Early rheumatoid arthritis; Methotrexate; Sulphasalazine; Therapy

Indexed keywords

ANTIRHEUMATIC AGENT; CHLOROQUINE; CORTICOSTEROID; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADVERSE DRUG REACTION; ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS;

EID: 0032693752     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. GORDON DA, HASTINGS DE: Rheumatoid arthritis clinical features. In: KLIPPEL JH and DIEPPE PA (Eds.): Rheumatology. St Louis, C.V. Mosby 1994; 3.4.1-14.
2. MÖTTÖNEN T, PAIMELA L, LEIRISALO-REPO M, KAUTIAINEN H, ILONEN J, HANNONEN P: Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998; 57: 533-9.
3. PINCUS T: Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037-41.
4. WILSKE KR, HEALEY LA: Remodelling the pyramid - A concept whose time has come. J Rheumatol 1989; 16: 565-7.
5. FRIES JF: Re-evaluating the therapeutic approach to rheumatoid arthritis: The "sawtooth" strategy. J Rheumatol 1990; 17: 12-15.
6. EMERY P, SALMON M: Early rheumatoid arthritis: Time to aim for remission? Ann Rheum Dis 1995; 54: 944-7.
7. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-22.
8. PINCUS T, STEIN CM, WOLFE F: "No evidence of disease" in rheumatoid arthritis using methotrexate in combination with other drugs: A contemporary goal for rheumatology care? Clin Exp Rheumatol 1997; 15: 591-6.
9. CLARK P, TUGWELL P, BENNET K et al.: A meta-analysis of injectable gold in rheumatoid arthritis. The Cochrane Library, 1998.
10. SUAREZ-ALMAZOR ME, BELSECK E, SHEA B, HOMICK J, WELLS G, TUGWELL P: Antimalarials versus placebo in rheumatoid arthritis. The Cochrane Library, 1998.
11. SUAREZ-ALMAZOR ME, BELSECK E, SHEA B, WELLS G, TUGWELL P: Sulphasalazine versus placebo in rheumatoid arthritis. The Cochrane Library 1998.
12. SUAREZ-ALMAZOR ME, BELSECK E, SHEA B, WELLS G, TUGWELL P: Methotrexate versus placebo in rheumatoid arthritis. The Cochrane Library 1998.
13. SUAREZ-ALMAZOR ME, BELSECK E, SHEA B, WELLS G, TUGWELL P: Cyclophosphamide versus placebo in rheumatoid arthritis. The Cochrane Library 1998.
14. VAN DER HEIJDE DMFM, VAN RIEL PL, NUVER-ZWART IH, VAN DE PUTTE LBA: Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-years follow-up. Lancet 1990; 335: 539.
15. CASH JM, KLIPPEL JH: Second-line drug therapy for rheumatoid arthritis. N Eng J Med 1994; 19: 1368-75.
16. MÖTTÖNEN T, PAIMELA L, AHONEN J, HELVE T, HANNONEN P, LEIRISALO-REPO M: Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum 1996; 39: 996-1005.
17. SOKKA T, KAUTIAINEN H, HANNONEN P: A retrospective study of treating patients with various combinations of slow-acting anti-rheumatic drugs in a county hospital. Scand J Rheumatol 1997; 26: 440-3.
18. BORIGINI MJ, PAULUS HE: Combination therapy. In: BROOKS PM and FURST DE (Eds.): Innovative Treatment Approaches for Rheumatoid Arthritis. Baillière's Clin Rheumatol 1995; 689-710.
19. PINCUS T: Aggressive treatment of early rheumatoid arthritis to prevent joint damage. Bull Rheum Dis 1998; 47: 2-7.
20. VERHOEVEN AC, BOERS M, TUGWELL P: Combination therapy in rheumatoid arthritis: Updated systematic review. Br J Rheumatol 1998; 37; 612-19.
21. HAAGSMA CJ, VAN RIEL PICM, DE JONG AJL, VAN DE PUTTE LBA: Combination of sulfasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082-8.
22. DOUGADOS M, COMBE B, CANTAGREL A et al.: Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220-225.
23. VAN DEN BORNE BE, LANDEWE RB, GOEITHE HS et al.: Combination therapy in recent onset rheumatoid arthritis: A randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998; 25: 1493-8.
24. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
25. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Lancet 1999; 353; 1568-73.
26. PROUDMAN SM, RICHARDSON C, GREEN MJ et al.: Treatment of poor prognosis early RA: Conventional therapy with sulfasalazine vs. aggressive therapy with methotrexate, cyclosporin A and intra-articular steroids. Arthritis Rheum 1997; 40 (Suppl.): S192 (abstract).
27. CONAGHAN PG, WAKEFIELD RJ, O'CONNOR et al.: IA corticosteroids prevent progression of erosions in MTX treated eaily RA - An MRI/ RHUS study. Arthritis Rheum 1998; 41 (Suppl); S238 (abstract).
28. VAN DER HEIDE A, JACOBS JW, BIJLSMA JW et al.: The effectiveness of early treatment with "second-line" anti-rheumatic drugs. A randomised, controlled trial. Ann Intern Med 1996; 124: 699-707.
29. EGSMOSE C, LUND B, BORG G et al.: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-13.
30. MUNRO R, HAMPSON R, MCENTEGART A et al.: Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: Results of a 5-year prospective study. Ann Rheum Dis 1998; 57: 88-93.
31. CHAN K-W, FELSON D, YOOD R, WALKER A: The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994; 37: 814-20.
32. BOERS M, TUGWELL P, FELSON DT et al.: World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994: 21 (Suppl. 41): 86-9.
33. PINALS RS, MASI AT, LARSEN RA, and The Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
34. HANNONEN P, MÖTTÖNEN T, HAKOLA M, OKA M: Sulfasalazine in early rheumatoid arthritis. A double blind 48 week prospective, placebo controlled study. Arthritis Rheum 1993; 36: 1501-9.
35. EBERHARDT KB, RYDGREN LC, FETTERSSON H, WOLLHEIM FA: Early rheumatoid arthritis - Onset, course, and outcome over 2 years. Rheumatol Int 1990; 10: 135-42.
36. PREVOO MLL, VAN GESTEL AM, VAN'T HOF MA, VAN RIJSWIJK MH, VAN DE PUTTE LBA, VAN RIEL PICM: Remission in a prospective study of patients with rheumatoid arthritis. ARA preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35: 1101-5.
37. EBERHARDT K, RYDGREN L, FEX B, SVENSSON B, WOLLHEIM FA: D-penicillamine in early rheumatoid arthritis: Experience from a 2-year double blind placebo controlled study. Clin Exp Rheumatol 1996; 14: 625-31.
38. HARRISON BJ, SYMMONS DPM, BRENMAN P et al.: Inflammatory polyarthritis in the community is not a benign disease: Predicting functional disability one year after presentation. J Rheumatol 1996; 23: 1326-31.
39. TEN WOLDE S, BREEDVELD FC, HERMANS J et al.: Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347: 347-52.
40. BOERS M: The case of corticosteroids in the treatment of early rheumatoid arthritis. Rheumatotogy 1999; 38: 95-102.
41. CORKILL M, KIRKHAM BW, CHIKANZA IC, GIBSON T, PANAYI GS: Intramuscular depot methyprednisolone induction of chrysotherapy in rheumatoid arthritis: A randomized clinical trial. Br J Rheumatol 1990; 29: 274-9.
42. VAN GESTEL AM, LAAN RFJM, HAAGSMA CJ, VAN DE PUTTE LBA, VAN RIEL PLCM: Oral steroids as bridge therapy in RA patients starting with parenteral gold. A randomized double blind placebo controlled trial. Br J Rheumatol 1995; 34: 347-51.
43. KIRWAN JR and the Arthritis and Rheumatism Council Low-Dose Glucocorticosterioid Study Group: The effects of glucocorticosteroids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-6.
44. O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
45. WEYAND CM, HICOK KC, CONN DL, GORONZY JJ: The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117: 801-6.